Skip to main content

Table 3 Clinical data of included studies for the efficacy of antiviral treatment on the development of HCC in patients with CHC

From: Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis

Study Nationality Age Duration of follow up Study format Genotype NOS Treatment HCC/Total treatment HCC/Control Histology
Mazella G et al. (1996) [23] Italy Tx: 53, control: 54 (mean) mean 32 months P unknown 7 IFN-α or lymphoblastoid 5/193 9/92 Child A LC
Bruno S et al.(1997) [24] Italy Tx 56, control: 59 (mean) median 68 months P 62% type 1b 7 IFN-α 6/83 16/80 LC (mainly Child A)
Fattovich G et al. (1997) [25] Italy Tx: 53, control: 57 (mean) mean 60 months R unknown 8 IFN-α 7/193 16/136 LC
Serfaty L et al. (1998) [26] France Tx: 55, control: 56 (mean) median 40 months P 48% 1b 7 IFN-α 2/59 9/44 Knodell 10 (mean)
Benvegnù L et al.(1998) [27] Italy Tx: 56.7, control: 59.5 (mean) mean 71.5 months P unknown 8 IFN 4/75 20/77 Child A LC
International Interferon-α Hepatocellular Carcinoma Study Group (1998) [28] Italy and Argentina 54 (median) 36 months R unknown 7 IFN-α or lymphoblastoid 21/232 48/259 unknown
Imai Y et al.(1998) [29] Japan unknown Tx: 47.6, control: 46.8 (median) R unknown 7 IFN-α 28/419 19/144 F3,4: 37% in Tx, 53% in control
Yoshida H et al. (1999) [30] Japan Tx: 49.5, control: 53.6 (mean) median 4.3 years R 70.3% type 1 7 IFN-α or IFN-β or combination 89/2400 59/490 F3,4: 33.1% in Tx, 33.8% in control
Okanoue T et al. (1999) [31] Japan 42.6–57.6 (mean) mean 39.5–67.1 months R unknown 7 IFN-α or lymphoblastoid 52/1148 22/55 F3,4: 34% in Tx, F4: 100% in control
Valla DC et al. (1999) [32] France Tx: 57, control: 56 (mean) mean 160 weeks RCT unknown   IFN-α 5/47 9/52 compensated LC
Ikeda K et al. (2001) [33] Japan 57 (median) median 7.6 years R unknown 7 IFN-α or IFN-β 32/113 271/581 LC
Gramenzi A et al. (2001) [34] Italy Tx: 57.9, control: 58.1 (mean) median 55–58 months P unknown 7 IFN-α 6/72 19/72 LC (mainly Child A)
Nishiguchi S et al. (2001) [35] Japan Tx: 54.7, control: 57.3 (mean) mean 8.2 years RCT 75.6% type 2   IFN-α 12/45 33/45 unknown
Testino G et al. (2002) [16] Italy Tx: 55.3, control: 56.8 (mean) mean 95.4 months R 55% type 1b, 45% type 2 8 IFN-α 12/51 24/71 Child A LC
Coverdale SA et al. (2004) [36] Australia Tx: 37, control: 38 (median) median 9 years P 39.6% type 1 7 IFN-α 26/384 7/71 Scheuer fibrosis score 2
Azzaroli F et al. (2004) [37] Italy 55.1 (mean) 5 years RCT 64.4% type 1b   IFN-α with RBV 2/71 9/30 LC
Shiratori Y et al. (2005) [38] Japan Tx: 57, control: 61 (median) median 6.8 years P 71.9% type 1b 8 IFN-α or lymphoblastoid 84/271 35/74 unknown
Yu ML et al. (2006) [39] Taiwan Tx: 46.9, control: 43.6 (mean) mean 5.18–5.15 years R 46.2% type 1 8 IFN-α with or without RBV 51/1057 54/562 LC 15.6% in Tx, 12.1% in control
Sinn DH et al. (2008) [40] Korea 48.4–58.2 (mean) median 55.2 months R 48.6% type 2 7 IFN/PegIFN with or without RBV 14/490 122/647 F3,4: 49% in Tx, F4: 33% in control
Di Martino V et al. (2011) [41] France unknown median 59 months R 57.9% type 1 7 IFN with or without RBV, or PegIFN with RBV 9/184 5/184 55.5% F2 or greater
Tateyama M et al. (2011) [42] Japan 57 (median) mean 8.2 years R 72.1% type 1b 8 IFN/PegIFN with or without RBV 110/373 63/334 F3,4: 34.1%
Maruoka D et al. (2012) [43] Japan 50.4–54 (mean) mean 9.9 years R 73.6% type 1 8 IFN-α/IFN-β with or without RBV 85/577 35/144 F3,4: 24.3% in Tx, F4: 43.1% in control
Cozen ML et al. (2013) [44] US 50.98 (mean) mean 10 years R 68.7% type 1 8 IFN-α with or without RBV 11/159 9/199 F3,4: 19% (30.2% in Tx, 10.1% in control)
Aleman S et al. (2013) [45] Sweden 51 (mean) mean 5.3 years R 50% type 1 8 PegIFN with RBV 32/303 14/48 LC
Cozen ML et al. (2016) [46] US 51.4 (mean) mean 8.5 years P 71.6% type 1 or 4 8 IFN-α with RBV 43/692 84/1519 LC 15.8% in Tx, 5.3% in control
  1. HCC hepatocellular carcinoma, CHC chronic hepatitis C, NOS Newcastle-Ottawa scale, Tx treatment group, R retrospective cohort study, P prospective cohort study, RCT randomized controlled study, IFN interferon, PegIFN pegylated interferon, RBV ribavirin, LC liver cirrhosis